“…The greatest obstacles to BC treatment are the high tumor recurrence rates and lack of non-invasive, inexpensive, and sensitive specific biological markers for tumor monitoring 17 , 18 . Over the past decades, the limitations of cystoscopy, including invasiveness and high cost, have led to the development of several urinary-based diagnostic methods for BC surveillance, including urinary cytology 10 , 19 , fluorescence in situ hybridization 20 , 21 , urinary protein detection (BTA-STAT) 22 , 23 , NMP22 24 – 26 , and others 27 . However, all these biomarkers have limitations and must be combined with others for successful malignancy monitoring, which adds to the financial burden on patients 27 .…”